001     1037247
005     20250813203212.0
024 7 _ |a 10.1093/neuonc/noae082
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a 10.34734/FZJ-2025-00580
|2 datacite_doi
024 7 _ |a 38695575
|2 pmid
024 7 _ |a WOS:001269694700001
|2 WOS
037 _ _ |a FZJ-2025-00580
082 _ _ |a 610
100 1 _ |a Wang, Justin Z
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
260 _ _ |a Oxford
|c 2024
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754987750_30977
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.Keywords: extra-axial; meningioma; methylation; molecular; neurofibromatosis 2; nonmalignant; radiotherapy.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Landry, Alexander P
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Raleigh, David R
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Sahm, Felix
|0 0000-0001-5441-1962
|b 3
700 1 _ |a Walsh, Kyle M
|0 0000-0002-5879-9981
|b 4
700 1 _ |a Goldbrunner, Roland
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Yefet, Leeor S
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Tonn, Jörg C
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Gui, Chloe
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Ostrom, Quinn T
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Barnholtz-Sloan, Jill
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Perry, Arie
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Ellenbogen, Yosef
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Hanemann, C Oliver
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Jungwirth, Gerhard
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Jenkinson, Michael D
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Tabatabai, Ghazaleh
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Mathiesen, Tiit I
|0 P:(DE-HGF)0
|b 17
700 1 _ |a McDermott, Michael W
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Tatagiba, Marcos
|0 P:(DE-HGF)0
|b 19
700 1 _ |a la Fougère, Christian
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Maas, Sybren L N
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 22
700 1 _ |a Albert, Nathalie L
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Brastianos, Priscilla K
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Ehret, Felix
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Minniti, Giuseppe
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Lamszus, Katrin
|0 P:(DE-HGF)0
|b 27
700 1 _ |a Ricklefs, Franz L
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Schittenhelm, Jens
|0 0000-0002-9168-6209
|b 29
700 1 _ |a Drummond, Katharine J
|0 P:(DE-HGF)0
|b 30
700 1 _ |a Dunn, Ian F
|0 P:(DE-HGF)0
|b 31
700 1 _ |a Pathmanaban, Omar N
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Cohen-Gadol, Aaron A
|0 P:(DE-HGF)0
|b 33
700 1 _ |a Sulman, Erik P
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Tabouret, Emeline
|0 P:(DE-HGF)0
|b 35
700 1 _ |a Le Rhun, Emelie
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Mawrin, Christian
|0 P:(DE-HGF)0
|b 37
700 1 _ |a Moliterno, Jennifer
|0 P:(DE-HGF)0
|b 38
700 1 _ |a Weller, Michael
|0 0000-0002-1748-174X
|b 39
700 1 _ |a Bi, Wenya
|0 P:(DE-HGF)0
|b 40
700 1 _ |a Gao, Andrew
|0 P:(DE-HGF)0
|b 41
700 1 _ |a Yip, Stephen
|0 P:(DE-HGF)0
|b 42
700 1 _ |a Niyazi, Maximilian
|0 P:(DE-HGF)0
|b 43
700 1 _ |a Aldape, Kenneth
|0 0000-0001-5119-7550
|b 44
700 1 _ |a Wen, Patrick Y
|0 P:(DE-HGF)0
|b 45
700 1 _ |a Short, Susan
|0 P:(DE-HGF)0
|b 46
700 1 _ |a Preusser, Matthias
|0 0000-0003-3541-2315
|b 47
700 1 _ |a Nassiri, Farshad
|0 P:(DE-HGF)0
|b 48
700 1 _ |a Zadeh, Gelareh
|0 0000-0002-6637-4502
|b 49
|e Corresponding author
773 _ _ |a 10.1093/neuonc/noae082
|g Vol. 26, no. 10, p. 1742 - 1780
|0 PERI:(DE-600)2094060-9
|n 10
|p 1742 - 1780
|t Neuro-Oncology
|v 26
|y 2024
|x 1522-8517
856 4 _ |u https://juser.fz-juelich.de/record/1037247/files/PDF.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1037247
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 22
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-11
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21